Ainos Aligns Capital Structure With 2H 2025 Execution Roadmap; Announces Stock Consolidation
Ainos (NASDAQ:AIMD) announced a 1-for-5 stock consolidation effective June 30, 2025, aimed at attracting institutional investors and maintaining Nasdaq listing compliance. The consolidation will automatically convert every 5 shares into 1 share, with fractional shares paid in cash.
The company is entering a commercial execution phase in 2H 2025, focusing on two main verticals: AI Nose, an AI-powered scent digitization platform entering scaled field testing across senior care, robotics, and semiconductor manufacturing, and VELDONA®, a low-dose oral interferon in clinical development for both human and veterinary applications including feline chronic gingivostomatitis, Sjögren's syndrome, and HIV-related oral warts.
Ainos (NASDAQ:AIMD) ha annunciato una consolidazione azionaria 1-per-5 con efficacia dal 30 giugno 2025, volta ad attrarre investitori istituzionali e mantenere la conformità ai requisiti di quotazione Nasdaq. La consolidazione convertirà automaticamente ogni 5 azioni in 1 azione, con il pagamento in contanti delle frazioni di azioni.
L'azienda entrerà nella fase di esecuzione commerciale nella seconda metà del 2025, concentrandosi su due principali settori: AI Nose, una piattaforma di digitalizzazione degli odori basata su intelligenza artificiale che inizierà test su larga scala in ambiti come l'assistenza agli anziani, la robotica e la produzione di semiconduttori, e VELDONA®, un interferone orale a basso dosaggio in sviluppo clinico per applicazioni umane e veterinarie, inclusa la gengivostomatite cronica felina, la sindrome di Sjögren e le verruche orali correlate all'HIV.
Ainos (NASDAQ:AIMD) anunció una consolidación de acciones 1 por 5 que entrará en vigor el 30 de junio de 2025, con el objetivo de atraer inversores institucionales y mantener el cumplimiento de los requisitos de cotización en Nasdaq. La consolidación convertirá automáticamente cada 5 acciones en 1 acción, y las fracciones de acciones se pagarán en efectivo.
La compañía entrará en una fase de ejecución comercial en la segunda mitad de 2025, enfocándose en dos verticales principales: AI Nose, una plataforma de digitalización de olores impulsada por IA que comenzará pruebas a gran escala en cuidados para personas mayores, robótica y fabricación de semiconductores, y VELDONA®, un interferón oral de baja dosis en desarrollo clínico para aplicaciones humanas y veterinarias, incluyendo la gingivoestomatitis crónica felina, el síndrome de Sjögren y las verrugas orales relacionadas con el VIH.
Ainos (NASDAQ:AIMD)는 2025년 6월 30일부로 1주당 5주 병합(주식 통합)을 발표했으며, 이는 기관 투자자 유치 및 나스닥 상장 요건 준수를 위한 조치입니다. 이번 병합으로 5주가 자동으로 1주로 전환되며, 소수점 주식은 현금으로 지급됩니다.
회사는 2025년 하반기에 상업적 실행 단계에 진입할 예정이며, 두 가지 주요 분야에 집중합니다: AI Nose는 인공지능 기반 향기 디지털화 플랫폼으로, 노인 돌봄, 로봇 공학, 반도체 제조 분야에서 대규모 현장 테스트를 시작할 예정입니다. VELDONA®는 임상 개발 중인 저용량 경구용 인터페론으로, 고양이 만성 치은구내염, 쇼그렌 증후군, HIV 관련 구강 사마귀 등 인간 및 수의학적 적용을 포함합니다.
Ainos (NASDAQ:AIMD) a annoncé une consolidation d'actions au ratio de 1 pour 5, effective à partir du 30 juin 2025, visant à attirer des investisseurs institutionnels et à maintenir la conformité aux exigences de cotation Nasdaq. La consolidation convertira automatiquement chaque lot de 5 actions en 1 action, les fractions d'actions étant réglées en espèces.
L'entreprise entre dans une phase d'exécution commerciale au second semestre 2025, en se concentrant sur deux secteurs principaux : AI Nose, une plateforme de numérisation des odeurs alimentée par l'IA, qui débutera des tests à grande échelle dans les domaines des soins aux personnes âgées, de la robotique et de la fabrication de semi-conducteurs ; et VELDONA®, un interféron oral à faible dose en développement clinique pour des applications humaines et vétérinaires, incluant la gingivostomatite chronique féline, le syndrome de Sjögren et les verrues orales liées au VIH.
Ainos (NASDAQ:AIMD) gab eine 1-zu-5-Aktienzusammenlegung bekannt, die am 30. Juni 2025 wirksam wird. Ziel ist es, institutionelle Investoren anzuziehen und die Einhaltung der Nasdaq-Listenanforderungen sicherzustellen. Die Zusammenlegung wandelt automatisch jeweils 5 Aktien in 1 Aktie um, wobei Bruchstücke in bar ausgezahlt werden.
Das Unternehmen tritt in die kommerzielle Umsetzungsphase in der zweiten Jahreshälfte 2025 ein und konzentriert sich auf zwei Hauptbereiche: AI Nose, eine KI-gestützte Plattform zur Digitalisierung von Düften, die umfangreiche Feldtests in den Bereichen Seniorenbetreuung, Robotik und Halbleiterfertigung durchführt, sowie VELDONA®, ein oral verabreichter Interferon-Niedrigdosierungswirkstoff in klinischer Entwicklung für menschliche und veterinärmedizinische Anwendungen, darunter feline chronische Gingivostomatitis, Sjögren-Syndrom und HIV-bedingte orale Warzen.
- Stock consolidation aims to attract broader institutional interest
- AI Nose platform entering scaled field testing across multiple industries
- Multiple VELDONA clinical programs advancing toward key milestones
- Strategic positioning for commercial execution phase in 2H 2025
- Dilutive impact on existing shareholders through 1:5 share reduction
- Stock consolidation suggests potential Nasdaq listing compliance concerns
Insights
Ainos announces 5:1 reverse stock split while highlighting pipeline progress; likely aims to maintain Nasdaq listing amid undisclosed price challenges.
Ainos has announced a 5:1 reverse stock split effective June 30, 2025, which will reduce outstanding shares while proportionately increasing the stock price. This consolidation appears strategically timed with their commercial execution roadmap for second half of 2025, when the company expects significant developments across their business lines.
Reading between the lines, this reverse split likely addresses compliance concerns with Nasdaq's minimum bid price requirement of $1 per share, though the company frames it as positioning to attract institutional investors. Notably, the announcement lacks specific information about current stock price, suggesting it may have fallen below compliance thresholds.
The company is simultaneously advancing two primary technology platforms: the AI Nose scent digitization platform entering field testing across multiple industries, and VELDONA, a low-dose oral interferon being developed for both human and veterinary applications. However, the announcement provides no concrete timelines, financial projections, or partnership details that would substantiate commercial viability.
Shareholders should note that while reverse splits mathematically adjust share price upward, they don't fundamentally change company valuation. The consolidation will reduce share count by 80%, with fractional shares paid in cash. This restructuring affects all equity instruments including outstanding warrants (AIMDW), with proportional adjustments to exercise prices.
This appears to be primarily a technical financial maneuver to maintain listing requirements while buying time for commercial developments to materialize in late 2025. Investors should watch for substantive updates on the clinical programs and AI Nose pilots mentioned to assess whether meaningful revenue potential follows this capital restructuring.
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 26, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it will implement a consolidation of its common stock ("stock consolidation"), effective at the opening of trading on June 30, 2025. This strategic action positions Ainos to attract broader institutional interest as it enters a commercial execution phase in the second half of 2025 and supports the Company's continued Nasdaq listing.
This action aligns with the Company's 2025 execution roadmap, as Ainos advances pilot programs of its AI-powered scent digitization platform, AI Nose, and clinical development of VELDONA®, its low-dose oral interferon, across both human and veterinary indications.
"This decision positions us to deliver long-term value as we scale execution across multiple verticals, " said Eddy Tsai, Chairman, President and CEO of Ainos. "AI Nose is now entering scaled field testing across senior care, robotics, and semiconductor manufacturing, with momentum building through the second half of 2025. At the same time, our VELDONA® programs, including veterinary trials for feline chronic gingivostomatitis (FCGS) and human studies for Sjögren's syndrome and HIV-related oral warts, are advancing toward key clinical milestones."
"With scaled AI Nose pilots launching in Japan and Taiwan, and multiple VELDONA clinical programs entering key stages, the second half of 2025 may deliver several high-impact commercial milestones that position us for meaningful value creation. " Mr. Tsai concluded.
Following the stock consolidation, every five (5) shares of issued and outstanding common stock will automatically be combined and convert into one (1) share. The stock consolidation reduces the number of shares of the Company's outstanding common stock. No fractional shares will be issued, and holders of fractional shares will be paid out in cash for the fractional portion. The Company's common stock will continue trading under the same Nasdaq ticker symbol (AIMD), with a new CUSIP number, 00902F402.
As a result of the stock consolidation, the number of shares of common stock owned by each shareholder will be reduced by a factor of five (5), and the opening price per share on the effective date is expected to increase to approximately five times the pre-consolidation price. Proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards and warrants and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the conversion or exercise price, as applicable. There will be no change to the number of authorized shares or the par value per share of the Company's common stock.
Additional information will be available in the Company's current report on Form 8-K filed with the U.S. Securities and Exchange Commission.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering SmellTech and immune therapeutics. Its AI Nose platform and smell language model digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose", is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the ratio of Ainos (AIMD) stock consolidation announced for June 2025?
How will the AIMD stock consolidation affect shareholders?
What are the main business segments Ainos (AIMD) is focusing on in 2H 2025?
Will Ainos stock symbol change after the June 2025 consolidation?
What clinical trials is Ainos (AIMD) currently advancing with VELDONA?
